Usted buscó: pegaptanib (Inglés - Estonio)

pegaptanib
pegaptaniib

macugen pegaptanib
macugen pegaptaniib

0.3 mg pegaptanib sodium.
mg annust.

macugen 0.3mg injection pegaptanib
macugen 0, 3 mg süstelahus pegaptaniib

the active substance is pegaptanib.
toimeaine on pegaptaniibnaatrium.

pegaptanib injected into the eye blocks vegf.
pegaptaniibi süstimine silma blokeerib vegf-i.

pegaptanib is metabolised by endo- and exonucleases.
pegaptaniib metaboliseeritakse endo- ja eksonukleaaside poolt.

pegaptanib has not been studied in pregnant women.
rasedatel naistel ei ole pegaptaniibi kasutamist uuritud.

macugen 0.3 mg solution for injection pegaptanib sodium
macugen 0, 3 mg süstelahus pegaptaniibnaatrium

there are no studies on the carcinogenic potential of pegaptanib.
5. 3 prekliinilised ohutusandmed

macugen 0.3 mg solution for injection pegaptanib sodium intravitreal use
macugen 0, 3 mg süstelahus pegaptaniibnaatrium klaaskehasiseseks manustamiseks

pegaptanib pharmacokinetics have not been studied in patients with hepatic impairment.
maksakahjustusega patsientidel ei ole pegaptaniibi farmakokineetikat uuritud.

the active substance in macugen, pegaptanib, is an ‘aptamer’.
macugeni toimeaine pegaptaniib on aptameer.

pegaptanib does not accumulate in the plasma when administered intravitreally every 6 weeks.
pegaptaniib ei kuhju plasmas, kui seda manustatakse klaaskehasse iga 6 nädala tagant.

pegaptanib is metabolised by nucleases and therefore cytochrome p450 mediated drug interactions are unlikely.
pegaptaniib metaboliseeritakse nukleaaside poolt ja seetõttu on koostoimed tsütokroom p450 süsteemi vahendusel metaboliseeritavate ravimitega ebatõenäolised.

in rabbits, pegaptanib is eliminated as parent drug and metabolites primarily in the urine.
küülikutel elimineeritakse pegaptaniib lähteravimina ja metaboliitidena peamiselt uriiniga.

each single dose pre-filled syringe delivers a dose of 0.3 mg pegaptanib in 90 microlitres.
iga üheannuseline süstel sisaldab pegaptaniibi 0,3 mg annust 90 mikroliitris.

pegaptanib sodium has not been adequately studied in patients with creatinine clearance below 20 ml/min.
pegaptaniibnaatriumi ei ole piisavalt uuritud patsientidel kreatiniini kliirensiga alla 20 ml/min.

patients who were re-randomized to discontinue pegaptanib after one year, lost visual acuity during the second year.
patsientidel, kes randomiseeriti pärast ühte aastat pegaptaniibravi katkestamise rühma, kadus nägemisteravus teise aasta jooksul.

macugen must not be used in people who are hypersensitive (allergic) to pegaptanib or any of the other ingredients.
macugeni ei tohi kasutada patsiendid, kes on pegaptaniibi või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).